SG11201503716RA - 2-pyridone compound - Google Patents

2-pyridone compound

Info

Publication number
SG11201503716RA
SG11201503716RA SG11201503716RA SG11201503716RA SG11201503716RA SG 11201503716R A SG11201503716R A SG 11201503716RA SG 11201503716R A SG11201503716R A SG 11201503716RA SG 11201503716R A SG11201503716R A SG 11201503716RA SG 11201503716R A SG11201503716R A SG 11201503716RA
Authority
SG
Singapore
Prior art keywords
pyridone compound
pyridone
compound
Prior art date
Application number
SG11201503716RA
Other languages
English (en)
Inventor
Shoichi Kuroda
Yudai Imai
Takanori Kawaguchi
Keiko Fusegi
Masahiro Bohno
Hajime Asanuma
Tomomichi Chonan
Nagaaki Sato
Souichi MONMA
Shigetada Sasako
Marie MIZUTANI
Shin Itoh
Takumi Okada
Hirofumi Ota
Seishi Ishiyama
Original Assignee
Nissan Chemical Ind Ltd
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Ind Ltd
Publication of SG11201503716RA publication Critical patent/SG11201503716RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SG11201503716RA 2012-11-13 2013-11-12 2-pyridone compound SG11201503716RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 2-ピリドン化合物

Publications (1)

Publication Number Publication Date
SG11201503716RA true SG11201503716RA (en) 2015-06-29

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503716RA SG11201503716RA (en) 2012-11-13 2013-11-12 2-pyridone compound

Country Status (25)

Country Link
US (1) US9695148B2 (enExample)
EP (1) EP2921489B1 (enExample)
JP (1) JP5963025B2 (enExample)
KR (1) KR102160841B1 (enExample)
CN (1) CN104768944B (enExample)
AU (1) AU2013345930B2 (enExample)
BR (1) BR112015010823A2 (enExample)
CA (1) CA2891406C (enExample)
DK (1) DK2921489T3 (enExample)
ES (1) ES2641469T3 (enExample)
HU (1) HUE034557T2 (enExample)
IL (1) IL238701B (enExample)
IN (1) IN2015DN03869A (enExample)
MX (1) MX361479B (enExample)
MY (1) MY173812A (enExample)
NO (1) NO2921489T3 (enExample)
NZ (1) NZ707832A (enExample)
PH (1) PH12015501056A1 (enExample)
PL (1) PL2921489T3 (enExample)
PT (1) PT2921489T (enExample)
RU (1) RU2662157C2 (enExample)
SG (1) SG11201503716RA (enExample)
TW (1) TWI591064B (enExample)
WO (1) WO2014077235A1 (enExample)
ZA (1) ZA201503323B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 2−ピリドン化合物を含有する医薬
KR20170003524A (ko) * 2014-05-13 2017-01-09 닛산 가가쿠 고교 가부시키 가이샤 2-피리돈 화합물의 제조 방법
CN114209694A (zh) 2018-05-31 2022-03-22 华领医药技术(上海)有限公司 含有葡萄糖激酶激活剂和ppar受体激活剂的药物组合及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
ES2226811T3 (es) 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
ES2362949T3 (es) 2006-06-08 2011-07-15 Eli Lilly And Company Carboxamidas substituidas como antagonistas del receptor metabotrópico de grupo i.
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
PT2173737E (pt) * 2007-07-17 2012-03-19 Bristol Myers Squibb Co Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
CA2782727C (en) * 2009-12-04 2017-03-14 Taisho Pharmaceutical Co., Ltd. 2-pyridone compounds
JP2013010750A (ja) 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd 2−ピリドン化合物を含有する医薬

Also Published As

Publication number Publication date
AU2013345930A1 (en) 2015-06-04
NO2921489T3 (enExample) 2018-02-03
PT2921489T (pt) 2017-12-01
WO2014077235A1 (ja) 2014-05-22
PH12015501056B1 (en) 2015-07-27
BR112015010823A2 (pt) 2017-07-11
IN2015DN03869A (enExample) 2015-10-02
IL238701A0 (en) 2015-06-30
TWI591064B (zh) 2017-07-11
RU2015122717A (ru) 2017-01-10
CA2891406A1 (en) 2014-05-22
CN104768944B (zh) 2017-03-29
MX361479B (es) 2018-12-06
TW201434826A (zh) 2014-09-16
DK2921489T3 (en) 2017-10-16
EP2921489B1 (en) 2017-09-06
HK1207856A1 (en) 2016-02-12
PL2921489T3 (pl) 2018-01-31
PH12015501056A1 (en) 2015-07-27
JPWO2014077235A1 (ja) 2017-01-05
KR102160841B1 (ko) 2020-09-28
MY173812A (en) 2020-02-24
KR20150082301A (ko) 2015-07-15
AU2013345930B2 (en) 2017-08-24
US9695148B2 (en) 2017-07-04
US20160289208A1 (en) 2016-10-06
CN104768944A (zh) 2015-07-08
MX2015005884A (es) 2015-12-09
IL238701B (en) 2018-10-31
ES2641469T3 (es) 2017-11-10
RU2662157C2 (ru) 2018-07-24
ZA201503323B (en) 2016-08-31
NZ707832A (en) 2019-03-29
CA2891406C (en) 2021-03-16
HUE034557T2 (en) 2018-02-28
EP2921489A1 (en) 2015-09-23
EP2921489A4 (en) 2016-04-06
JP5963025B2 (ja) 2016-08-03

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201220843D0 (en) Compound
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
PL2836495T3 (pl) Związki tetrahydropirolotiazynowe
GB201209096D0 (en) Compounds
GB201219820D0 (en) Compounds
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
ZA201503323B (en) 2-pyridone compound
GB201217310D0 (en) Compounds
SG11201504418TA (en) Pyridone compound
GB201216448D0 (en) Compound
GB201222716D0 (en) Compound
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218776D0 (en) Compounds